Comparative Pharmacology
Head-to-head clinical analysis: ADENOCARD versus SORINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOCARD versus SORINE.
ADENOCARD vs SORINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is an endogenous purine nucleoside that acts on A1 and A2 adenosine receptors. It slows conduction through the AV node, interrupts reentry pathways, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT).
Selective beta-1 adrenergic receptor antagonist; decreases cardiac output, heart rate, and blood pressure.
6 mg IV bolus over 1-2 seconds, followed by 20 mL saline flush; if no conversion to sinus rhythm within 1-2 minutes, give 12 mg IV bolus; may repeat 12 mg once more if needed.
5 mg orally once daily, increased after 4 weeks to 10 mg orally once daily if tolerated and needed.
None Documented
None Documented
Terminal half-life is less than 10 seconds; clinically, the effect is very transient due to rapid cellular uptake and metabolism.
4-6 hours in healthy adults; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion of metabolites; adenosine is rapidly metabolized intracellularly to inosine and adenosine monophosphate, with less than 1% excreted unchanged in urine.
Renal (80% unchanged) and biliary (15% as metabolites); 5% fecal.
Category C
Category C
Antiarrhythmic
Antiarrhythmic